A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)
7/24/2013

Alabama, Arizona, Arkansas, California, Florida, Kansas, Montana, North Carolina, Ohio, Oklahoma, South Carolina, Tennessee, Utah. clinicaltrials.gov

Related Summaries